Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines

  • Authors:
    • Jardena Nordenberg
    • Israela Perlmutter
    • Gad Lavie
    • Einat Beery
    • Orit Uziel
    • Chaya Morgenstern
    • Eyal Fenig
    • Abraham Weizman
  • View Affiliations

  • Published online on: October 1, 2005     https://doi.org/10.3892/ijo.27.4.1097
  • Pages: 1097-1103
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sigma receptors are present in cancer cell lines. The aim of the present study is to evaluate the anti-tumor activity of a series of sigma 1, sigma 2 and sigma 1/2 ligands in B16 melanoma cell lines. Proliferation, apoptosis, intracellular ATP content, cell cycle and molecular regulators were analyzed. Cell growth was determined using the sulforhodamine B (SRB) colorimetric cytotoxicity assay. Apoptosis was assessed by flow cytometry and DNA fragmentation, using ELISA cell death assay. ATP content was measured spectrofluorometrically and cell cycle analysis was performed by flow cytometry. The cytpolasmic and nuclear expression of cell cycle regulatory molecules, cyclin D and CDK2 (cyclin dependent kinase 2) were determined by Western blot analysis and quantified by densitometry. The sigma ligands in single digit micromolar concentrations inhibited B16 and multidrug-resistant B16 COL/R cell growth, leading to cell death at higher concentrations. The potency order was: haloperidol, reduced-haloperidol, ifenprodil tartrate, opipramol and carbetapentane citrate. B16 COL/R cells were to some extent, less sensitive to sigma ligands. Further studies have shown that the growth inhibitory effect of sigma ligands could be attributed to G1 arrest of the cell cycle, mediated by a marked decrease in cytoplasmic and nuclear cyclin D and CDK2 protein expression, though haloperidol induced loss of cell viability due to apoptosis. Sigma ligands induced an early decrease in ATP content. These data stimulated us to examine the combined anti-proliferative activity of haloperidol and the tyrosine kinase inhibitor imatinib mesylate (STI 571), on SK-MEL-28 human melanoma cells. Preliminary experiments demonstrated a marked synergistic interaction between the two agents.

Related Articles

Journal Cover

October 2005
Volume 27 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nordenberg J, Perlmutter I, Lavie G, Beery E, Uziel O, Morgenstern C, Fenig E and Weizman A: Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. Int J Oncol 27: 1097-1103, 2005
APA
Nordenberg, J., Perlmutter, I., Lavie, G., Beery, E., Uziel, O., Morgenstern, C. ... Weizman, A. (2005). Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. International Journal of Oncology, 27, 1097-1103. https://doi.org/10.3892/ijo.27.4.1097
MLA
Nordenberg, J., Perlmutter, I., Lavie, G., Beery, E., Uziel, O., Morgenstern, C., Fenig, E., Weizman, A."Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines". International Journal of Oncology 27.4 (2005): 1097-1103.
Chicago
Nordenberg, J., Perlmutter, I., Lavie, G., Beery, E., Uziel, O., Morgenstern, C., Fenig, E., Weizman, A."Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines". International Journal of Oncology 27, no. 4 (2005): 1097-1103. https://doi.org/10.3892/ijo.27.4.1097